Radioactive Isotopes for Adjuvant Cancer Therapy

Ariel, Irving M.

doi:10.1001/archsurg.1964.01320020008002

Cited by 32 publications

(5 citation statements)

References 4 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Although it has been reported that in properly treated patients the majority of microspheres do collect in the tumor vasculature (3,(21)(22)(23)(24), additional safety, lower toxicity, and likely greater antitumor outcomes should be realized with improved accuracy of microsphere deposition. There is a sizeable amount of literature on the use of 90 Y microspheres dating back to the early 1950s (25)(26)(27), and there are currently large worldwide clinical trials enrolling hundreds of patients each. Hence the fundamentals of the technique are well known regarding the current state of the art in the delivery of both resin and glass 90 Y microspheres (4,28).…”

Section: Discussionmentioning

confidence: 99%

Computer Modeling of Yttrium-90–Microsphere Transport in the Hepatic Arterial Tree to Improve Clinical Outcomes

Kennedy¹,

Kleinstreuer²,

Basciano³

et al. 2010

International Journal of Radiation Oncology*Biology*Physics

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Computer Modeling of Yttrium-90–Microsphere Transport in the Hepatic Arterial Tree to Improve Clinical Outcomes

Kennedy¹,

Kleinstreuer²,

Basciano³

et al. 2010

International Journal of Radiation Oncology*Biology*Physics

View full text Add to dashboard Cite

“…The first 90Y treatment in patients with liver metastases from CRC was published in 1964 by Ariel [9]. Combined SIRT and chemotherapy provided better response rates than either treatment alone.…”

Section: Discussionmentioning

confidence: 99%

Selective Internal Radiation Therapy with SIR-Spheres for the Treatment of Unresectable Colorectal Hepatic Metastases

Cianni

Urigo

Notarianni

et al. 2009

Cardiovasc Intervent Radiol

View full text Add to dashboard Cite

The purpose of this study was to evaluate the effectiveness of colorectal cancer (CRC) liver metastasis radioembolization with yttrium-90 (Y90), assessing toxicity and survival rates in patients with no response to chemotherapy through our 3-year experience. From February 2005 to January 2008, we treated 41 patients affected by CRC from a cohort of selective internal radiation therapy patients treated at our institution. All patients examined showed disease progression and arrived for our observation with an abdominal CT, a body PET, and a hepatic angiography followed by gastroduodenal artery coiling previously performed by us. We excluded patients with a bilirubin level>1.8 mg/dl and pulmonary shunt>20% but not patients with minor extrahepatic metastases. On treatment day, under fluoroscopic guidance, we implanted a dose of Y90 microspheres calculated on the basis of liver tumoral involvement and the body surface area formula. All patients were discharged the day after treatment. We obtained, according to Response Evaluation Criteria on Solid Tumors, a complete response in 2 patients, a partial response in 17 patients, stable disease in 14 patients, and progressive disease in 8 patients. In all cases, we obtained a carcinoembryonic antigen level decrease, especially in the week 8 evaluation. Technical success rate was 98% and technical effectiveness estimated at 3 months after treatment was 80.5%. Side effects graded by Common Terminology Criteria on Adverse Events were represented by one grade 4 hepatic failure, two grade 2 gastritis, and one grade 2 cholecystitis. The median survival and the progression-free survival calculated by Kaplan-Meier analysis were 354 and 279 days, respectively. In conclusion, according to our 3-year experience, Y90 SIR-Spheres radioembolization is a feasible and safe method to treat CRC liver metastases, with an acceptable level of complications and a good response rate.

show abstract

“…In 2006, hepatic metastases from colorectal cancer claimed more than 800,000 lives, whereas another 662,000 died of hepatoma (1). Implanting 90 Y-microspheres in hepatic tumors has garnered significant interest in the past 8 years, but its first clinical trials date back to the early 1960s (2). The therapeutic advantage in this approach is based on the unique dual vascular supply of the liver.…”

Section: Introductionmentioning

confidence: 99%

Treatment Parameters and Outcome in 680 Treatments of Internal Radiation With Resin 90Y-Microspheres for Unresectable Hepatic Tumors

Kennedy¹,

McNeillie²,

Dezarn³

et al. 2009

International Journal of Radiation Oncology*Biology*Physics

234

174

View full text Add to dashboard Cite

Radioactive Isotopes for Adjuvant Cancer Therapy

Cited by 32 publications

References 4 publications

Computer Modeling of Yttrium-90–Microsphere Transport in the Hepatic Arterial Tree to Improve Clinical Outcomes

Computer Modeling of Yttrium-90–Microsphere Transport in the Hepatic Arterial Tree to Improve Clinical Outcomes

Selective Internal Radiation Therapy with SIR-Spheres for the Treatment of Unresectable Colorectal Hepatic Metastases

Treatment Parameters and Outcome in 680 Treatments of Internal Radiation With Resin 90Y-Microspheres for Unresectable Hepatic Tumors

Contact Info

Product

Resources

About